Lenalidomide gastro-retentive sustained-release tablet and preparation method thereof
US12226530B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Sep 29, 2018 |
| Grant date | Feb 18, 2025 |
| Priority date | — |
| Expiry date | Sep 20, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/454
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention discloses a lenalidomide gastro-retentive sustained-release tablet and a preparation method thereof. The sustained-release tablet comprises 3 wt % to 14 wt % of lenalidomide, 14 wt % to 68 wt % of release enhancer with low bulk density, 23 wt % to 70 wt % of sustained-release material with low bulk density, and the balance of other pharmaceutically acceptable excipients, wherein the bulk density of the release enhancer ranges from 0.24 g/cm3 to 0.52 g/cm3; and the bulk density of the sustained-release material ranges from 0.29 g/cm3 to 0.51 g/cm3. The sustained-release tablet of the invention is in a floating state in a gastric environment, is not directly discharged from a stomach due to gastric emptying, has an effect of gastric retention, and is not easily discharged with substances contained in the stomach, and has a high drug bioavailability and small side effects.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.